CD14 and COVID-19: To test this hypothesis, we added plasma from patients with urosepsis or COVID-19 or from corresponding healthy controls, to CD34+ HSPCs or CD34+ HSPCs lacking the IL-6 receptor and observed a marked reduction in CD14+ cell production in the latter group (Fig. 3B).